FDA Drug Recalls

Recalls / Class II

Class IID-0030-2026

Product

Gabapentin Capsules, USP, 100 mg, 100 Capsules (10 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268, USA, NDC 0904-6665-61

Brand name
Gabapentin
Generic name
Gabapentin
Active ingredient
Gabapentin
Route
Oral
NDCs
0904-6665, 0904-6666, 0904-6667
FDA application
ANDA090858
Affected lot / code info
Lot # M04950, Exp Date: 01/2026; Lot # M04989, M04990, Exp Date: 02/2026; Lot # M05056, Exp Date: 04/2026; Lot # M05150, Exp Date: 07/2026; Lot # M05290, Exp Date: 11/2026; Lot # M05312, M05342, Exp Date: 01/2027; Lot # M05369, M05386, Exp Date: 02/2027.

Why it was recalled

Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .

Recalling firm

Firm
The Harvard Drug Group LLC
Manufacturer
Major Pharmaceuticals
Type
Voluntary: Firm initiated
Address
7000 Cardinal Pl, Dublin, Ohio 43017-1091

Distribution

Distribution pattern
US Nationwide.

Timeline

Recall initiated
2025-10-10
FDA classified
2025-10-17
Posted by FDA
2025-10-29
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0030-2026. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.